NEW YORK — August 19, 2026 — Merck and Moderna announced this morning that a personalized mRNA cancer vaccine met its primary endpoint in a Phase 3 trial, the first time a therapy of this kind has done so in a randomized late-stage study of any cancer.
The trial, INTerpath-001, enrolled 1,137 patients with high-risk stage IIB through IV cutaneous melanoma whose tumors had already been surgically removed. Participants received either intismeran autogene — also known as V940 or mRNA-4157 — together with Merck's checkpoint inhibitor Keytruda, or Keytruda alone. At a planned interim analysis, the combination significantly extended recurrence-free survival, and also improved distant metastasis-free survival, a secondary endpoint measuring how long patients went without the cancer appearing elsewhere in the body.
The companies described the improvements as statistically significant and clinically meaningful, and reported no new safety signals. They have not yet released the underlying numbers, which will be presented at a medical meeting and submitted to regulators.
Dr. Dennis Porto, a double board-certified dermatologist and Mohs micrographic surgeon, says the result lands differently for physicians who treat melanoma surgically.
“The hardest conversation in my practice is not the diagnosis. It is the follow-up visit where I tell someone their margins are clear and I still cannot promise them it will not come back. This is the first thing in a long time that speaks directly to that gap.”
What a personalized cancer vaccine actually is
The word vaccine is doing unusual work here. This is not a shot given to healthy people to prevent melanoma from developing. It is a treatment given after surgery, to patients who already had the disease, designed to reduce the chance that it returns.
The personalization is the mechanism. Every tumor accumulates its own set of mutations, and those mutations produce abnormal proteins — neoantigens — that exist nowhere else in the body. A sample of the removed tumor is sequenced, a set of those neoantigens is selected, and mRNA encoding them is manufactured for that one patient. Injected, it instructs their cells to display those tumor-specific markers, training the immune system to recognize any remaining melanoma cells as foreign.
“When I excise a melanoma, I am removing what I can see and what the microscope can confirm. What keeps recurrence rates where they are is the cells that already left before anyone knew the lesion was there. Surgery cannot chase those. An immune system that has been taught what to look for can.”
Keytruda works differently and complementarily. It releases a brake that tumors use to evade immune attack. The rationale for pairing them is straightforward: the vaccine tells the immune system what the target looks like, and the checkpoint inhibitor keeps it from being switched off once it finds it.
Why this readout matters more than the earlier ones
The approach is not new, and neither is encouraging melanoma data. The Phase 2b KEYNOTE-942 study, whose five-year results were reported at ASCO earlier this year, showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death with the same combination.
Those numbers drew a great deal of attention. They also came from 157 patients in a trial that was not designed to be definitive, and an attempt to convert them into an accelerated approval did not succeed.
“Dermatology has a long history of promising early data that does not survive a proper randomized trial. A Phase 2b signal in 157 people tells you something is worth studying. It does not tell you it works. What changed today is the size and the design, not the idea.”
What is still unknown
A good deal, and it is worth being direct about it. The companies released an announcement, not data. No hazard ratios, no survival curves, no subgroup analyses. The trial is ongoing, and this was an interim analysis.
“Clinically meaningful is a phrase, not a number. Until I can see the curves and how long the follow-up runs, I have no way to tell a patient how much benefit to expect. I am optimistic. I am not yet able to be specific, and I would be suspicious of any physician who is this week.”
Overall survival — whether patients live longer, not merely longer without recurrence — will take more time to establish. Manufacturing is another open question: each dose is built for one person from their own tumor, which is a considerable logistical undertaking at scale, and cost and access will follow from how well that is solved.
The trial also studied patients with stage IIB and higher disease. Most melanoma diagnosed in the United States is thinner and earlier than that, and nothing here speaks to those patients.
What this does not change
Dr. Porto is emphatic that the news should not be read as reducing the importance of finding melanoma early.
“This is adjuvant therapy. Every single patient in that trial had surgery first, and every one of them was high risk because their melanoma was found late enough to be high risk. A thin melanoma caught early is still cured by excision alone, with a scar and no systemic treatment at all. Nothing announced today is better than that.”
The practical implications are unchanged: watch for the spot that is new, changing, growing, bleeding, or simply behaving unlike the others, and get it evaluated. Daily photoprotection still prevents the mutations that make melanoma possible in the first place.
“The best outcome in melanoma remains a two-millimeter margin and a follow-up appointment. Everything we are talking about today exists because somebody's cancer got past that point.”
The bigger picture
Beyond melanoma, the result is being read as validation of an approach rather than of a single product. Intismeran is in trials across several other tumor types, and the platform argument — that mRNA allows a bespoke therapy to be designed and manufactured in weeks — only holds if it can be shown to work somewhere first.
“Melanoma is usually where this kind of thing gets tested, because it carries a heavy mutation burden and it responds to immunotherapy. That makes it the friendliest possible proving ground. Whether this translates to cancers that are quieter immunologically is a genuinely open question, and melanoma answering it first is not the same as it being answered.”
Regulatory filings are expected to follow. Any approval would be the first for an mRNA-based cancer therapy.
Dr. Dennis Porto, MD, MPH, FAAD is a double board-certified dermatologist and Mohs micrographic surgeon, and a Clinical Assistant Professor at Mount Sinai, where he teaches skin cancer surgery to dermatology resident physicians. He treats patients virtually through SkinCare.MD. A spot that concerns you can be reviewed through the conditions covered by his practice.
Media inquiries and interview requests may be directed through the contact information at skincare.md.